Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.

نویسندگان

  • Mei-Chiun Tseng
  • Ku-Chou Chang
چکیده

PURPOSE This work was undertaken to review current evidence of cost-effectiveness analysis (CEA) on thrombolysis for acute ischemic stroke. METHODS An electronic search via PubMed, from 1995 until May 2004, was performed. The methods undertaken by these studies were examined with particular attention to their modeling assumptions, sources of data, and outcome measures. RESULTS Three comprehensive CEAs of rtPA (recombinant tissue plasminogen activator) for acute ischemic stroke were reviewed. These studies were from the United States, Canada, and the United Kingdom. All these studies employed the perspective of a healthcare system and used a Markov decision-analytic modelling approach. Estimates of effectiveness of rtPA were based on the National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Trial, literature-derived values or a stroke registry. In each study, functional outcome measured by the modified Rankin Scale was used to represent health states, and quality-adjusted life year gained was the health outcome summary measure. The cost-effectiveness of rtPA therapy varied in magnitude, but seemingly with same positive implications. CONCLUSIONS Cost-effectiveness analysis requires information on an intervention's effectiveness and country-specific sources of epidemiological and resource utilization data, most of which are not yet available in Taiwan. Despite the limitations, CEA is essential if a healthcare system would like to contain costs while maintaining, or improving, quality of care.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke

BACKGROUND Intravenous recombinant tissue plasminogen activator (IV rtPA) is recommended treatment for acute ischemic stroke patients, but the cost-effectiveness of IV rtPA within different time windows after the onset of acute ischemic stroke is not well reviewed. AIMS To conduct a literature review of the cost-effectiveness studies about IV rtPA by treatment times. SUMMARY OF REVIEW A lit...

متن کامل

The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...

متن کامل

A clinical study investigating the three months prognosis of patients with ischemic stroke treated with recombinant tissue plasminogen activator (rt-PA) and its effective factors

Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has acceptable results in patients with stroke. This study aimed to evaluate the three months prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA).Methods: This cross-sectional prospective study was conducted on 30 patients with cerebral ischemic stroke with the National Insti...

متن کامل

Intravenous Thrombolysis for Acute Ischemic Stroke due to Cardiac Myxoma; A Case Report

Myxoma may cause systemic embolization and frequently presents as ischemic stroke. There has been debates whether it is safe to use recombinant tissue plasminogen activator (rt-PA) in patients with cardiac myxoma who are presented with ischemic stroke at emergency department. we describe a young case of atrial myxoma with initial presentation of acute cerebral infarction symptoms who was treate...

متن کامل

Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.

BACKGROUND AND PURPOSE The objective of this study was to determine the cost-effectiveness of intra-arterial treatment within the 0- to 6-hour window after intravenous tissue-type plasminogen activator within 0- to 4.5-hour compared with intravenous tissue-type plasminogen activator alone, in the US setting and from a social perspective. METHODS A decision analytic model estimated the lifetim...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Acta neurologica Taiwanica

دوره 13 3  شماره 

صفحات  -

تاریخ انتشار 2004